J&J seeks US authorization for COVID-19 booster dose


Johnson & Johnson has filed a request with the FDA to authorize emergency use of a booster dose of its COVID-19 vaccine for individuals 18 and older who previously received the firm's single-dose vaccine. The filing was based on late-stage trial data that showed a booster dose administered 56 days after the first shot offered 94% protection against symptomatic COVID-19, and 100% protection against severe illness.

Full story:

AIChE SmartBrief

Chemical engineering news

Designed specifically for chemical engineers, AIChE SmartBrief is a FREE weekly e-mail newsletter. It helps chemical engineers stay informed on the business and technology developments affecting our profession.